enVVeno Medical will host a conference call and webcast on September 21, 2022

News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here.

– Conference call with live audio webcast to be held on Wednesday, September 21st 4:30 p.m. ET

IRVINE, Calif./ACCESSWIRE/September 19, 2022/ enVVeno Medical Corporation (NASDAQ: NVNO) (“enVVeno” or the “Company”), a company setting new standards of care for the treatment of venous disease, today announced that it will host a conference call and webcast Wednesday, September 21, 2022 at 4:30 p.m. ET.

Interested participants and investors can access the conference call by dialing (877) 407-9708 (domestic) or (201) 689-8259 (international) and referencing conference call ID: 13732870. live webcast will be accessible on the Events page of the Investors section of the enVVeno website, envveno.comand will be archived for 90 days.

About enVVeno Medical Corporation

enVeno Medical (Nasdaq: NVNO) is an Irvine, California-based late-stage clinical-stage medical device company focused on advancing innovative (tissue-based) bioprosthetic solutions to improve the standard of care in the treatment of diseases venous. The Company’s flagship product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of chronic deep venous insufficiency (CDI). In healthy patients, valves inside the leg veins help pump blood up the leg and to the heart and lungs. CVI occurs when the valves inside the veins of the leg are damaged, causing blood to back up (reflux), pooling of blood in the lower leg, increased pressure in the veins of the leg (venous hypertension) and, in severe cases, venous hemorrhage from ulcers that are difficult to heal and become chronic. The VenoValve is designed to replace faulty valves and to help restore good blood circulation in the leg. The VenoValve is currently being evaluated in the pivotal SAVVE study.

Caution Regarding Forward-Looking Statements

This press release and any statements of shareholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the “Company”) relating thereto contain or may contain, among other things, certain “statements forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, but are not limited to, statements identified by words such as “plans”, “may”, “will”, “could”, “would”, “should”, “believes”, “s ‘expects’, ‘anticipates’, ‘estimates’, ‘intentions’, ‘plans’, ‘potential’ or similar expressions. These statements are based on the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results and timing may differ materially from those expressed or implied by forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on a variety of factors (many of which are beyond the Company’s control). Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.


Jenene Thomas, JTC Team, LLC
[email protected]
(833) 475-8247

THE SOURCE: enVeno Medical Corporation

See the source version on accesswire.com:

Comments are closed.